Novartis stays focused on the long-term

Novartis predicts its growth will see a resurgence during the second half of 2008. What about the meantime? The company will remain depressed by generic competition and by its loss of the irritable bowel drug Zelnorm, which was withdrawn from the market on safety concerns. (Since then, Novartis has agreed to restricted-access sales of the drug.)

On the plus side, the company says it expects to roll out 10 new products globally through 2008. And it's going to turn its cash flow toward shareholders, with stock repurchases in addition to the already announced $4 billion buy-back plan. 

- check out the AFX report

Related Articles:
Novartis shares slide after Zelnorm gets yanked. Report
EMEA committee rejects Novartis' Zelnorm. Report
Novartis highlights cancer pipeline. Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.